Joan Olschewske
Family · Hickory, NCNPI 1952315228
Payments from drug & device makers
Across 77 payments — averaging $18.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bayer$263
- Vanda Pharmaceuticals Inc.$163
- GSK$154
- Novo Nordisk$117
- Lilly USA, LLC$92
- Boehringer Ingelheim$62
- plus $561 from 20 others
What the payments were for
- Food & beverage$1,38698%
- Education$252%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bayer | 13 | $263 |
| Vanda Pharmaceuticals Inc. | 7 | $163 |
| GSK | 7 | $154 |
| Novo Nordisk | 8 | $117 |
| Lilly USA, LLC | 5 | $92 |
| Boehringer Ingelheim | 4 | $62 |
| Pfizer | 3 | $60 |
| Exact Sciences | 3 | $48 |
| Edwards Lifesciences | 3 | $48 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $40 |
| Currax Pharmaceuticals LLC | 2 | $38 |
| Almatica Pharma LLC | 2 | $31 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $28 |
| Phathom Pharmaceuticals, Inc. | 2 | $28 |
| Boston Scientific | 1 | $27 |
| Sanofi-aventis U.S. LLC | 1 | $26 |
| Abbott | 1 | $25 |
| AbbVie | 2 | $24 |
| Novartis | 2 | $24 |
| Dexcom, Inc. | 1 | $19 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Eisai Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| AstraZeneca | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Lundbeck LLC | 1 | $13 |
How this compares
$1,411 in reported general payments places this provider in the 75th percentile of 4,522 family providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 31 | $42,611 |
| FarxigaDapagliflozin Propanediol | 22 | $27,736 |
| TrulicityDulaglutide | 21 | $21,053 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 22 | $15,076 |
| EliquisApixaban | 16 | $14,943 |
| JardianceEmpagliflozin | 15 | $11,427 |
| BrilintaTicagrelor | 12 | $11,238 |
| Tresiba Flextouch U-100Insulin Degludec | 17 | $10,619 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 43 | $8,337 |
| Breo ElliptaFluticasone/Vilanterol | 12 | $7,967 |
| Arnuity ElliptaFluticasone Furoate | 12 | $2,830 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 100 | $2,563 |
| Novolog FlexpenInsulin Aspart | 13 | $1,759 |
| Ventolin HfaAlbuterol Sulfate | 30 | $1,700 |
| Gabapentin | 101 | $1,676 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog Mix 70-30 | $117 | $43,39142 claims |
| AstraZenecaFarxiga, Brilinta | $14 | $38,97434 claims |
| GSKAnoro Ellipta, Breo Ellipta, Arnuity Ellipta | $154 | $25,87446 claims |
| Lilly USA, LLCTrulicity | $92 | $21,05321 claims |
| PfizerEliquis | $60 | $14,94316 claims |
| Boehringer IngelheimJardiance | $62 | $11,42715 claims |
| Almatica Pharma LLCSertraline Hcl | $31 | $17917 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,522 family providers in North Carolina.
Other family in Hickory
- Kelly HolmesHickory$55K
- Tanya DyerHickory$21K
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.